𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

✍ Scribed by Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Kenneth Kar-Lung Yan; Angel Mei-Ling Chim; Hoi-Yun Chan; Chi-Hang Tse; Paul Cheung-Lung Choi; Anthony Wing-Hung Chan; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
256 KB
Volume
51
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatitis B e antigen as a predictor for
Hepatitis B e antigen as a predictor for hepatitis B e antigen–positive chronic hepatitis B patients with peginterferon alfa-2a therapy
✍ En-Qiang Chen; Hong Tang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 1 views

PROVE1 trial, 1 in which in the group with an identical treatment schedule, the percentage of patients obtaining SVR with respect to RVR was 75% only. In other words, RVR seems easier to obtain with telaprevir, but less frequently predicts a favorable treatment outcome. A possible explanation might

Prediction of sustained response to pegi
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline
✍ Milan J. Sonneveld; Vincent Rijckborst; Charles A. B. Boucher; Bettina E. Hansen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB 👁 1 views

Serum hepatitis B surface antigen (HBsAg) levels may reflect the immunomodulatory efficacy of pegylated interferon (PEG-IFN). We investigated within a large randomized trial whether quantitative HBsAg levels predict response to PEG-IFN in patients with hepatitis B e antigen (HBeAg)-positive chronic

Entecavir treatment for up to 5 years in
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B
✍ Ting-Tsung Chang; Ching-Lung Lai; Seung Kew Yoon; Samuel S. Lee; Henrique Sergio 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 371 KB 👁 1 views

Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)-022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)-positive CHB. A total of 183 entecavir-treated patients from E

Characterization of viral kinetics in pa
Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B
✍ I-Chin Wu; Nan-Haw Chow; Pin-Nan Cheng; Wen-Chun Liu; Kung-Chia Young; Wei-Lun C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract A study was conducted during a 1 year follow‐up to characterize the viral kinetics in hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B and to develop a model of predicting the probability of spontaneous HBeAg seroconversion. Fifty‐seven patients with HBeAg‐positive chronic hep

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60